Regulatory Information
Novazepra® is approved by relevant regulatory authorities in the countries where it is marketed.
Marketing Authorisation Holder (MAH)
GenomaLab Medical LLC
United Arab Emirates
Oman Representative
GenomaLab Healthcare LLC
Sultanate of Oman
Contact Information
For country-specific registration information, healthcare professionals may contact the local medical information team.
Availability Notice
Product availability and prescribing information may vary by country according to local regulatory requirements.
Disclaimer
Please refer to your local prescribing information before initiating treatment.